本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
MIAMI, Jan. 18, 2025 /PRNewswire/ -- The Moskowitz Law Firm, PLLC announces the preliminary approval of a proposed class action settlement that would benefit purchasers and legal title holders of Astrals Non-Fungible Tokens or Galaxy Tokens: On January 14, 2025, the United States District Court for the Southern District of Florida preliminarily approved a proposed settlement of a class action captioned Harper v. O'Neal, Case No. 23-CV-21912-MORENO. The settlement class includes persons and entities who, from May 24, 2022 to January 14, 2025, purchased Astrals NFTS and/or who, before January 14, 2025, purchased GLXY tokens. Claims for settlement benefits must be submitted by April 17, 2025. Objections to the settlement and requests for exclusion from the settlement must be received by March 3, 2025 in accordance with the instructions in the Class Notice, which is posted on the settlement website www.astralsnftsettlement.com. The Court will hold a Final Approval Hearing on April 1, 2025, at 9:30 a.m. For more information about the settlement and its terms please visit www.astralsnftsettlement.com. If you have questions about any matter in this Class Notice, please contact the following representative of Class Counsel, who can answer questions: Adam M. MoskowitzThe Moskowitz Law Firm, PLLCP.O. Box 653409Miami, FL 33175(305) 740-1423 adam@moskowitz-law.comservice@moskowitz-law.com
Transdermal GFR System (TGFR) is a first-in-kind product for point of care assessment of kidney function in patients with normal or impaired renal function. The transdermal GFR (tGFR) methodology has been designed to be effective across the adult population without input of age, weight, sex, gender, race, or ethnicity. More than 800 million people have Chronic Kidney Disease (CKD), one of the world's leading causes of mortality worldwide, with associated deaths increasing over the past two decades.1 ST. LOUIS, Jan. 18, 2025 /PRNewswire/ -- MediBeacon Inc. today announced the U.S. Food and Drug Administration (FDA) has approved the MediBeacon® TGFR for the assessment of kidney function in patients with normal or impaired renal function. The TGFR is comprised of the TGFR Sensor, TGFR Monitor, and Lumitrace® (relmapirazin) injection, a non-radioactive, non-iodinated fluorescent GFR tracer agent, which together allow assessment of kidney function by measuring the clearance rate of the fluorescent agent as it leaves the body. The system records Lumitrace fluorescence intensity transdermally as a function of time via a sensor placed on the skin. The TGFR Sensor records 2.5 fluorescent readings per second and the TGFR Monitor will display the average session tGFR reading at the patient's bedside or in the outpatient setting. The TGFR is validated for use in the assessment of Glomerular Filtration Rate (GFR) in patients with stable kidney function at the point of care. The TGFR utilizes an intravenous Lumitrace injection but does not require blood draws or urine analysis, unlike current methodologies requiring multiple blood draws or urine samples. In addition, current clinical practice measured GFR (mGFR) assessment requires sophisticated clinical laboratory analysis away from the patient's point of care. "The development of a system such as the TGFR that assesses a patient's kidney function without the need to use estimating equations is an important milestone for the nephrology community," said Dr. Mitchell Rosner, chair of the Department of Medicine at University of Virginia and a highly regarded expert who has authored numerous articles on the challenges of assessing kidney function. "We are excited to explore applications of the transdermal GFR methodology in patients where current clinical practice is understood to be suboptimal." Dr. Pierre Galichon, an active kidney researcher at the Sorbonne Université and an attending physician in kidney transplantation at Pitié-Salpêtrière Hospital in Paris, said: "It has long been a challenge to understand kidney function in the context of its interaction with other vital organs, such as the heart and lungs. My experience with MediBeacon products in preclinical use, as relayed in Scientific Reports,2 has been exciting, and I look forward to evaluating how transdermal GFR can be applied in clinical practice." "The approval of the TGFR by the FDA demonstrates our proprietary system can provide an effective option for assessing kidney function," said Steve Hanley, CEO of MediBeacon. "According to the National Kidney Foundation, CKD causes more deaths each year than breast cancer or prostate cancer. It is the under-recognized public health crisis.3 The potential applications for the TGFR are numerous, and we look forward to exploring them with clinicians both in the hospital and outpatient settings." The timing of FDA approval aligns well with the Q4 2024 publication by MediBeacon's Chief Scientific Officer, Dr. Richard Dorshow, et al. in Kidney International4 with data that supports the utility of MediBeacon's patented agent Lumitrace®. The TGFR met its primary efficacy endpoint as per agreement with the FDA by demonstrating a P30 value of 94% while recruiting patients with a range of GFR values and skin tones. P30 is defined as the percentage of GFR estimation falling within +/- 30% of measured GFR (mGFR) values. P30 Value Upper 95% Confidence Bounds Lower 95% Confidence Bounds 94.0 % 96.9 % 89.4 % In clinical studies no serious or severe adverse events have been observed. For more information, including the FDA Summary of Safety and Effectiveness Data, please refer to www.fda.gov. About MediBeacon Inc.MediBeacon is a medical technology company specializing in the advancement of fluorescent tracer agents and their transdermal detection. MediBeacon's use of proprietary fluorescent tracer agents coupled with transdermal detection technology focuses on providing vital and actionable measurement of organ function. MediBeacon owns over 55 granted U.S. patents and over 215 granted patents worldwide that provide extensive coverage of the MediBeacon® TGFR, including Lumitrace® injection, the sensor and algorithms, as well as other strategic uses of its proprietary pyrazine platform and sensor technology. The TGFR is approved for human use. Potential technology applications in gastroenterology, ophthalmology and surgery are in various stages of clinical development. MediBeacon is based in St. Louis, Missouri, with additional operations in Mannheim, Germany. For more information, please visit: www.medibeacon.com. About Lumitrace® (relmapirazin) injectionRelmapirazin is a non-radioactive, non-iodinated pyrazine-based compound, which has been engineered to be inert, highly fluorescent, and have the clearance properties of a GFR tracer agent in the body. The unique photophysical characteristics of Lumitrace have been designed to enable the collection of fluorescence data via a photodetector sensor placed on the skin. Data collected by the sensor measures the change in the intensity of Lumitrace fluorescence over time and is converted into a transdermal GFR (tGFR) by proprietary algorithms. In a phase 2 investigational study mGFR deduced from Lumitrace matched that of mGFR deduced from iohexol over a range of GFR values. See the peer reviewed article published in the October 2024 issue of Kidney International by Dorshow et al. IMPORTANT SAFETY INFORMATION FOR TGFR Indication for Use:The MediBeacon® Transdermal GFR System (TGFR) is intended to assess the Glomerular Filtration Rate (GFR) in adult patients with impaired or normal renal function by noninvasively monitoring fluorescent light emission from an exogenous tracer agent over time. This device has been validated in patients with stable renal function. The MediBeacon® TGFR is not approved for use in patients with GFR <15 ml/min/1.73 m2, GFR >120 ml/min/1.73m2, patients on dialysis, or anuric patients. The use of this device in patients with dynamic and rapidly changing renal function has not been validated. This device is not intended to diagnose acute kidney injury (AKI). The MediBeacon® TGFR Sensor and exogenous tracer agent, Lumitrace® injection, are single use and are only used with the MediBeacon® TGFR. The MediBeacon® TGFR Sensor is a single use device intended to attach to the patient's skin and excite fluorescence in Lumitrace® injection, the tracer agent, and measure the returning light intensity. The data is sent to the MediBeacon® TGFR Monitor. Lumitrace® is an injectable exogenous fluorescent tracer indicated for use with the MediBeacon® Transdermal GFR System (TGFR) for Glomerular Filtration Rate assessment. Contraindications: There are no known contraindications. Warnings and Precautions: See ifu.medibeacon.com for full instructions, warnings, and cautions. In clinical studies no serious or severe adverse events have been observed. Lumitrace® injection has light absorbance at 266nm and 435nm, and broad fluorescent emission at ~560nm when excited at ~440nm. Any drug activated at these wavelengths should not be used in conjunction with Lumitrace. Lumitrace injection may interfere with clinical laboratory tests. DO NOT ADMINISTER if the patient is expected to need clinical laboratory testing while Lumitrace is present in their system (up to 72 hours for renally-impaired patients). The presence of Lumitrace decreased B-Type Natriuretic Peptide (BNP) results by around 20% in limited testing. Bolus infusions may impact the GFR assessment temporarily while the vasculature-tissue equilibrium is re-established. During a TGFR session, the patient should be as still as possible, especially during the "Establishing Baseline" stage. The current system is designed to compensate for light activity such as reading or eating after the Baseline stage. 1 Epidemiology of chronic kidney disease: an update 2022, Kidney International Supplement, 2022 Apr;12(1):7-11. doi: 10.1016/j.kisu.2021.11.003., Csaba P Kovesdy 2 Pulmonary hypertension without heart failure causes cardiorenal syndrome in a porcine model, Scientific Reports (2023) 13:9130, Orieux et al, doi.org/10.1038/s41598-023-36124-13 National Kidney Foundation, Fast Facts (2024 Update), Updated as of 8/6/20244 Clinical validation of the novel fluorescent glomerular filtration rate tracer agent relmapirazin (MB-102), Kidney International, Volume 106, Issue 4, P679-687, October 2024, DOI: 10.1016/j.kint.2024.06.012
CHANGZHOU, China, Jan. 18, 2025 /PRNewswire/ -- EZGO Technologies Ltd. (Nasdaq: EZGO) ("EZGO" or "we", "our", or the "Company"), a leading short-distance transportation solutions provider in China, today announced its audited financial results for the fiscal year ended September 30, 2024 (the "Fiscal Year 2024"). Fiscal Year 2024 Financial Highlights (all results compared to the prior year period unless otherwise noted) Revenues were $21.1 million, an increase of 32.7%, which was primarily due to the increase of sales of battery packs resulting from the increased acceptance of our lithium battery packs in the market. Gross profit was $1.5 million, an increase of 32.5%. Gross margin was 7.1%, which remained stable with a slight decrease from 7.2% for the fiscal year 2023. Net loss was $8.1 million, an increase from net loss of $7.3 million for the fiscal year 2023, representing an increase of 11.4%, which was primarily raised from the increase in impairment of long-term equity investment. Basic and diluted loss per share attributable to shareholders was $2.80, compared to $5.91 for the fiscal year 2023. As of September 30, 2024, the Company had cash and cash equivalents of $3.5 million, compared to $17.3 million as of September 30, 2023. Management Commentary Mr. Jianhui Ye, Chief Executive Officer of EZGO, stated, "In the past fiscal year, the Company's operating revenue increased by over 30%, which was attributed to the timely adjustment of business strategies by the Company's management, their proactive response to new industry and market challenges, and the timely shift of business focusing on the lithium-ion battery (LIB) for low-speed e-bicycles. During the second quarter of this fiscal year, the e-bicycle business experienced a significant decline due to the "Nanjing EV Charging Station Massive Fire" accident, leading most dealers and consumers to adopt a wait-and-see attitude towards the existing stock of e-bicycles in the short term. In response to changes in the market and regulatory environment, the Company has shifted its business focus towards LIB, intensifying product development efforts and cooperation with LIB manufacturing partners. The Company has also introduced multiple safe and efficient LIB products to the market through various channels, rapidly capturing the LIB market for e-bicycles and e-tricycles. Additionally, the e-bicycle business has transitioned from channel marketing to direct client marketing, with a focus on developing the e-bicycle sharing and rental market. The aforementioned adjustment of business focus and new business layout have significantly tied up the Company's working capital, resulting in a substantial year-on-year decline in working capital at the end of this fiscal year. However, as the expansion of new LIB product channels gradually takes shape and the sales of electric vehicle begins to show results, the occupation of operating capital in these two business segments will be effectively alleviated. During the past fiscal year, the sales of the Company's electronic control system products declined slightly compared to the previous period, yet the gross profit margin remained high. With the business strategy of increasing research and development expense and continuous market development investment, this business line is expected to contribute persistently to improving the Company's overall profitability over the next three years. The intelligent robotics business is in the market introduction phase and has not yet formed sustained and stable order support. However, the Company will continue investing in research and development for this business line, aiming to build a new product matrix." Fiscal Year 2024 Financial Review Net revenues The following table identifies the disaggregation of our revenue from continuing operations and reportable segments for the fiscal years ended September 30, 2022, 2023 and 2024, respectively: Years Ended September 30, Segment 2022 2023 2024 Sales of batteries and battery packs Battery cells and packs segment $ 6,990,215 $ 8,245,966 $ 16,318,839 Sales of e-bicycles E-bicycle sales segment 9,405,103 4,276,147 2,899,541 Sales of electronic control system and intelligent robots Electronic control system and intelligentrobot sales segment - 2,344,373 1,401,783 Others 993,899 1,054,173 514,262 Net Revenue $ 17,389,217 $ 15,920,659 $ 21,134,425 Net revenues from continuing operations for the fiscal year ended September 30, 2024 (the "Fiscal Year 2024") was $21.1 million, an increase of 32.7% from $15.9 million for the fiscal year ended September 30, 2023 (the "Fiscal Year 2023"). The increase in revenue from Fiscal Year 2023 to Fiscal Year 2024 was mainly due to the increased sales of battery packs and partially offset by the decreased sales of e-bicycles and the decreased sales of electronic control system and intelligent robots. The revenue from sales of battery packs was $16.3 million for Fiscal Year 2024, an increase of 97.9% from $8.2 million for Fiscal Year 2023, due to the remarkable increase in sales volume derived by several large orders from major customers responding to the heightened market demand for high-performance battery solutions. In addition, such an increase mainly resulted from the increased acceptance of our lithium battery packs in the market and the development of the lead-acid battery market in Sichuan. Overall, our sales volume of lithium battery packs increased by 256.5% for the year ended September 30, 2024, compared to fiscal 2023. The revenue from sales of e-bicycles was $2.9 million for Fiscal Year 2024, a decrease of 32.2% from $4.3 million for Fiscal Year 2023 due to the decreased sales volume of the e-bicycles resulting from the fierce competition of the e-bicycle industry. The revenue from sales of electronic control systems and intelligent robots was $1.4 million for Fiscal Year 2024, a decrease of 40.2% from $2.3 million for Fiscal Year 2023, mainly due to the decrease of $1,510,225 in sales of intelligent robots and offset by the increase of $951,665 in sales of electronic control systems. The revenue from sales of electronic control systems increased significantly by 211.4 % for fiscal 2024 compared to fiscal 2023, primarily due to the increased emphasis on environmental protection and construction safety within the industrial machinery sector. The decrease in sales for intelligent robots is primarily attributed to the fact that our main clients were upgrading and renovating their park facilities, resulting in no demand for intelligent robots during fiscal 2024. Cost of revenues Cost of revenues was $19.6 million for Fiscal Year 2024, an increase of 32.8% from $14.8 million for Fiscal Year 2023, which was primarily due to the increase of manufacturing and purchase cost of battery packs for sales of batteries and battery packs, which is in line with the increase of revenues. Gross profit Gross profit was $1.5 million for Fiscal Year 2024, an increase of 32.5% from $1.1 million for Fiscal Year 2023. Gross profit margin remained relatively stable, with a slight decrease from 7.2% in fiscal 2023 to 7.1% in fiscal 2024. The gross profit from electronic control system and intelligent robot sales segment increased from 25.8% for fiscal 2023 to 47.3% for fiscal 2024, predominantly attributable to the enhanced contribution of electronic control system sales business with a higher gross profit margin. The electronic control system developed and manufactured by Changzhou Higgs was embedded with highly complex software and the limited competition in the market results in a relatively high gross profit margin of 47.3% for electronic control system sales, which accounts for 6.6% of our total revenue in fiscal 2024 compared to 5.0% in fiscal 2023. Selling and marketing expenses Selling and marketing expenses remained relatively stable at $0.6 million for Fiscal Year 2024, a slight decrease of 9.5% compared to fiscal 2023, primarily due to the decrease in advertisement and business promotion expenses, service expenses and travel expenses. Advertisement and business promotion expenses s decreased by $71,610 or 92.6% to $5,751 in fiscal 2024, mainly due to the reduced advertising demands as our existing customer base and sales force were sufficient to support our business development and expansion. Travel expenses decreased by $13,607 or 15.3% to $75,504 in fiscal 2024; Service expenses decreased by $15,297, or 78.3%, from $19,529 in fiscal 2023 to $4,232 in fiscal 2024. General and administrative expenses General and administrative expenses remained relatively stable at $4.3 million for Fiscal Year 2024, a slight decrease of 8.3% from $4.7 million for Fiscal Year 2023. The decrease was primarily attributed to (1) the decrease of the share-based compensation expense of $880,851; (2) the decrease of depreciation and amortization expenses of $257,460, or 76.3%, mainly due to the disposal of Property, plant and equipment, including production lines and buildings of Tianjin Dilang and Tianjin Jiahao and E-bicycle charging piles; (3) the decrease of the professional service fees of $191,352, which was mainly due to the decrease of the investment consultancy fee. The decrease was partially offset by (1) the increase of credit losses expense on accounts receivable of $837,863, or 168.4%, mainly due to the difficulties in collecting accounts receivable from individual dealers of e-bicycles who was facing fierce competition from the industry-leading enterprises, and (2) the liquidated damages expense of $138,806 due to the early termination of a procurement contract. Research and development expenses Research and development expenses was $0.9 million for Fiscal Year 2024, an increase of 37.0% from $0.7 million for Fiscal Year 2023. The increase was primarily attributed to (1) the increased expenses in research and development activities for engineering vehicle wireless measurement and control system and construction worker safety positioning system of $84,735; (2) the increased depreciation and amortization expenses of $191,676 due to the patents and software acquired in May 2023, which were partially offset by the decreased expenses of $28,084 in research and development activities due to the disposal of Tianjin Dilang. Income tax expense/benefit EZGO incurred an income tax benefit of $786,369 for Fiscal Year 2024. This was a result from the increased deferred tax assets of $681,785, mainly due to the recurring net loss in fiscal 2024. Net loss Net loss was $8.1 million for Fiscal Year 2024, compared to $7.3 million for Fiscal Year 2023. Financial Condition As of September 30, 2024, the Company had cash and cash equivalents of $3.5 million, and a fixed deposit receipt of $1.5million with a maturity date of December 21, 2024 compared to $17.3 million as of September 30, 2023. For additional information, please see EZGO's Annual Report on Form 20-F for the fiscal year ended September 30, 2024, which was filed with the U.S. Securities and Exchange Commission on January 17, 2025. About EZGO Technologies Ltd. Leveraging an Internet of Things (IoT) product and service platform and two e-bicycle brands, "EZGO" and "Cenbird," EZGO has established a business model centered on the design, manufacturing and sale of two-and three-wheeled electric vehicles, intelligent robots, complemented by electric vehicle accessories including batteries, charging piles and electronic control system. For additional information, please visit EZGO's website at www.ezgotech.com.cn. Investors can visit the "Investor Relations" section of EZGO's website at www.ezgotech.com.cn/Investor. Exchange Rate This announcement contains translations of certain Chinese Renminbi ("RMB") amounts into U.S. dollars ("US$") at specified rates solely for the convenience of the readers. Unless otherwise stated, all translations from RMB to US$ were made at the rate of RMB7.0176 to US$1.00, the exchange rate in effect as of September 30, 2024, the middle price of RMB exchange rate announced by the People's Bank of China. The Company makes no representation that the RMB or US$ amounts referred could be converted into US$ or RMB, as the case may be, at any particular rate or at all. Safe Harbor Statement This press release contains forward-looking statements as defined by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as "may," "will," "intend," "should," "believe," "expect," "anticipate," "project," "estimate," or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company's expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to, the following: the Company's goals and strategies; the Company's future business development; product and service demand and acceptance; changes in technology; economic conditions; the growth of the short-distance transportation solutions market in China and the other international markets the Company plans to serve; reputation and brand; the impact of competition and pricing; government regulations; fluctuations in general economic and business conditions in China and the international markets the Company plans to serve and assumptions underlying or related to any of the foregoing and other risks contained in reports filed by the Company with the Securities and Exchange Commission (the "SEC"), including the Company's most recently filed Annual Report on Form 20-F and its subsequent filings. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company's filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof. Investor Relations Contact At the Company:Shawn WenPhone: +86 13502829216Email: ir@ez-go.com.cn
佛羅里達州坦帕2025年1月18日 /美通社/ -- 全球創新藥物輸送科技領域的先鋒概念醫療公司 Concept Medical Inc 自豪地宣佈，「MAGICAL BTK」（經皮血管腔內成形術 (MagicTouch PTA) - Sirolimus 塗層球囊 (Sirolimus Coated Balloon) 與標準球囊血管成形術治療膝部以下 (BTK) 動脈疾病的隨機對照試驗）臨床試驗器材豁免 (IDE) 中樞試驗，成功招募了首位病人。Icahn School of Medicine at Mount Sinai 的 Prakash Krishnan 醫生和其團隊招募了首位病人，標誌著膝下周邊動脈疾病 (PAD) 病人治療方案發展的重要里程碑。 First patient enrollment in MAGICAL-BTK IDE Study in the United States. 在美國食品和藥物管理局 (FDA) 最近獲得 MagicTouch PTA 的 IDE 批准後，這次成功招募病人，預示著 Concept Medical 在美國的周邊臨床試驗計劃正式開始。由於 MagicTouch SCB 在冠狀動脈疾病的 IDE 研究正在進行中，Concept Medical 目前正積極參與冠狀動脈和周邊血管介入的兩項美國臨床試驗，可說是一項前所未有的成就，旨在改善病人的治療效果並提供更多治療選項。 Icahn School of Medicine at Mount Sinai 的 Prakash Krishnan 博士表示：「將第一名病人加入 MAGICAL BTK 試驗，是邁向改善周邊動脈疾病 (PAD) 病人膝蓋以下 (BTK) 疾病護理標準的重要一步。Sirolimus 塗層球囊科技，有可能顯著提升肢體搶救機率及病人生活品質。我很榮幸能夠參與這項具里程碑意義的研究，期待本研究將產生有意義的臨床證據。」 MAGICAL BTK 中樞試驗，旨在評估 MagicTouch PTA Sirolimus Coated Balloon 與標準經皮腔內血管成形術 (PTA) 治療膝下動脈疾病的安全性和有效性。12 個月時的主要測量終點為主要通暢率 (primary patency)，確保試驗結果著重於有意義的臨床結果。這項全球多中心研究由 Sahil Parikh 教授（主席）領導，其主要研究人員包括 Eric Secemsky 博士（Beth Israel Deaconess Hospital 和哈佛醫學院）、Brian DeRubertis 教授（NY Presbyterian Weill Cornell Medical Center 和 Cornell University Medical College）、Edward Choke 教授 (Northern Heart Hospital) 和 Osamu Iida 教授 (Osaka Keisatsu Hospital)。 Sahil Parikh 教授表示：「MAGICAL BTK 試驗的開始，預告了對慢性肌肉威脅性缺血症病人的治療新時代，並為數百萬名因腿部動脈循環不足而可能喪失肢體的病人帶來曙光。 」 Sirolimus 塗層球囊科技已重塑冠狀動脈和周邊動脈疾病管理，在亞洲和歐洲的大規模試驗中取得積極成果。現在，透過 MAGICAL BTK 試驗，美國病人有機會從這種突破性方法中獲益。與此同時，亞洲病人的加入將擴大全球病人群體，讓我們更全面地了解此療法對不同人群的益處。 「在 Concept Medical，我們對於創新和照顧病人的堅定承諾，促使我們不斷突破血管介入手術的極限，」創辦人兼董事總經理 Manish Doshi 博士表示：「MAGICAL BTK 的開始，進一步驗證了我們為全球臨床醫師和病人提供新一代循證解決方案的決心。我們的目標是重新定義當前標準，確保受 PAD 影響的病人獲得更好的治療效果，改善生活品質。」 隨著 MAGICAL BTK 試驗和 MAGICAL SFA IDE 試驗用於骨骼肌肉表面動脈 (SFA) 治療開始，Concept Medical 將為血管內治療帶來革命性的改變。此公司獨特的技術平台已提升冠狀動脈疾病的管理水準；如今透過擴展至周邊血管介入，Concept Medical 鞏固了其在推動以病人為導向的藥物輸送解決方案的領導地位。 Concept Medical 簡介 Concept Medical Inc. 總部位於佛羅里達州坦帕，業務遍佈全球，一直致力於透過藥物輸送技術的頂尖研究與開發，加強照顧病人的水準。其專利平台可將藥劑非常精確地傳送至血管管腔表面。Concept Medical 是 MagicTouch 系列 Sirolimus 塗層球囊 (Sirolimus Coated Balloons, SCBs) 的開發者，這是世界上第一個也是應用最廣的 SCB 技術，因其在治療冠狀動脈和周邊動脈疾病方面的多功能性和療效而備受認可。革命性的 MagicTouch 和 Abluminus 產品系列，已用於治療全球超過一百萬名病人，為血管治療樹立新標準。 有關更多資訊，請瀏覽 www.conceptmedical.com。
Long An International Port made its inaugural appearance at the 12th PorTech Asia Summit 2025 and left a strong impression by showcasing its vision for green and smart port development. KUALA LUMPUR, Malaysia, Jan. 17, 2025 /PRNewswire/ -- The PorTech Asia Summit has been held annually since 2005, attracting top global experts in the port and maritime industry. In 2025, the 12th PorTech Asia Summit took place in Kuala Lumpur, Malaysia on January 9-10, with the theme "Smart Green, Multi-Win." This event gathered 300 industry experts, port authorities, associations, and leading enterprises, contributing to a vibrant forum on developing smart and sustainable ports and promoting regional cooperation. Mr. Vo Quoc Huy, Chairman of the Board of Directors of Long An International Port, discussing with regional experts and partners. During the event, Mr. Vo Quoc Huy, Chairman of the Board of Directors of Long An International Port, shared insights on the sidelines of the conference, earning commendation from international experts. He emphasized, "Green transformation represents a comprehensive revolution in the production and operation process. In line with new regulations set to take effect in 2030, Long An International Port is committed to restructuring its entire value chain to minimize environmental impact and fulfill Vietnam's global commitments. Particularly for Long An International Port, we focus on the main objectives of raising awareness among employees, efficient use of resources, environmental quality management, prioritizing the use of green energy, promoting the application of information technology, and minimizing the impact on climate change." Long An International Port distinguishes itself as a leading seaport in Vietnam by employing world-class bulk and general cargo handling systems such as CATOS and MOST. By integrating state-of-the-art equipment and advanced technologies into its operational framework, the port has significantly enhanced its efficiency. This strategic optimization enables Long An International Port to swiftly and flexibly address the diverse requirements of its customers, solidifying its position as a pivotal player in the industry. As a featured speaker during the conference, a representative from Long An International Port shared a presentation on "Initiatives for the Economic Development and Green Logistics in Vietnam's Southern Key Economic Region." The presentation left a strong impression as the international audience was introduced to a versatile, modern seaport committed to sustainable development, garnering significant interest from regional partners. The presentation highlighted comprehensive port solutions, showcasing the application of technology in port management and operations. The port's openness to networking, knowledge sharing, and experience exchange paves the way for new cooperation opportunities, contributing to the sustainable development of the region and Vietnam's logistics sector. Long An International Port's participation at the 12th PorTech Asia Summit 2025 serves as a platform to showcase Long An Province and Vietnam as a dynamic, modern, and integrated location to the international community, with strong focus on sustainable development. Media Contacts: ROSE CASTILLO YAP (Ms) HEAD OF PORT COMMUNICATIONS & MARKETING Long An International Port Telephone: +84 272 374 1515 Mobile: +84 76 351 6656 Email: roseyap@longanport.com
印度邦加羅爾2025年1月18日 /美通社/ -- 首屈一指的全球數碼轉型公司Microland已被認定為《2024年ISG供應商鏡頭研究》（ISG Providers Lens Study 2024）智能自動化服務領域（Intelligent Automation Services）資訊科技營運人工智能（Artificial Intelligence for IT Operations，簡稱「AIOps」）象限美國區領導者（Leader）。 Microland Recognized as a Leader in ISG Providers Lens Study 2024 for Intelligent Automation Services 《2024年ISG供應商鏡頭研究》（ISG Providers Lens Study 2024）強調了智能自動化服務供應商（Intelligent Automation Service Providers）所提供的全面自動化策略，將不斷發展的技術能力與在整個組織中擴展的潛力相結合。該研究強調了以客戶為中心的設計、專門構建的自動化以及商業經驗在建立卓越績效指標中的重要性。 Microland的AIOps平台「Intelligeni」提供基於人工智能的資訊科技營運自動化和即時分析，提升混合資訊科技管理、簡化事件解決流程，並改善可擴展性。該公司基於「Intelligeni」平台的創新自動化營運模式，打造了能夠在不造成中斷的情況下適應變化的韌性資訊科技環境。Intelligeni透過其全面的可觀察性平台，實現與多種監控來源的全棧集成，提供準確的健康評估和對資訊科技營運的全面可視化。 「我們榮幸地被認定為《2024年ISG供應商鏡頭研究》（ISG Providers Lens Study 2024）智能自動化服務（Intelligent Automation Services）領導者（Leader），」Microland高級副總裁兼全球平台部門主管Satish Sukumar表示：「這一認可證明了我們致力於透過創新的人工智能驅動解決方案，提升資訊科技韌性和效率，為客戶提供穩定的體驗並推動業務增長。」 Microland主席Sam Mathew表示「這一認可凸顯了我們不懈的努力，致力於透過智能的人工智能驅動解決方案，為企業提供支持，這些解決方案不僅優化資訊科技營運，還為可持續且可擴展的數碼轉型奠定基礎。」他補充道：「這是我們的驕傲時刻，因為我們持續幫助客戶應對複雜挑戰，並自信地實現韌性。」 研究主編Ashwin Gaidhani表示：「Microland為實施AIOps的客戶提供了完整的平台和指導，為其資訊科技基礎設施提供端到端的洞察。」 《2024年ISG供應商鏡頭研究》（ISG Providers Lens Study 2024）為業務和資訊科技決策者提供了重要的決策依據，呈現了相關服務供應商的優勢和劣勢，根據不同市場（包括美國和歐洲）進行差異化定位，並聚焦於各市場的發展。該研究還提供了對多模式人才需求高漲以及負責任的自動化實踐重要性的洞察見證。 如需了解更多關於Microland的AIOps解決方案以及《2024年ISG供應商鏡頭研究》（ISG Providers Lens Study 2024）的資訊，請瀏覽https://www.microland.com/analyst-insights/isg-provider-lens-study-intelligent-automation-services-2024。 Microland簡介 Microland是一間總部位於印度本加盧魯的領先資訊科技基礎設施服務和顧問公司，已獲35年實際業務成果，紀錄良好。現時，隨著企業明白網路乃現代數碼系統功能與效率的基礎和支援創新。因此，我們提供新一代技術（例如人工智能、自動化營運和平台驅動的解決方案等），從而推動組織卓越營運、靈活和全球生產力。我們超過4,600位專家的團隊，在亞洲、澳洲、歐洲、中東和北美洲100多個國家／地區提供服務。團隊在網絡、雲端、數據中心、網絡安全、服務管理、應用程式和自動化上，提供頂尖科技解決方案。Microland的創新策略獲得領先業界分析師認可，並致力強力治理、環境可持續發展，並建立予各種人才發展的包容工作場所。當企業與Microland合作時，便可以連結最佳人才、技術和解決方案，創造獨一無二的價值。 如需詳細資訊，請瀏覽www.microland.com。 傳媒聯絡：sobia.sahar@microland.com Leader in the Artificial Intelligence for IT Operations (AIOps) Quadrant
A12 藝術空間
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
